期刊
MOLECULES
卷 26, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/molecules26061787
关键词
microsampling; DBS; VAMS; mAbs; TDM; inflammatory diseases
资金
- Slovenian Research Agency (ARRS) [P1-0189]
Monoclonal antibodies have been developed for the treatment of inflammatory diseases with complex pharmacokinetic properties. Therapeutic drug monitoring with serum matrix faces challenges in accessibility, leading to the exploration of alternative methods like dried blood spots and microsampling techniques. The obstacle of hematocrit may be addressed through novel analytical techniques and contemporary microsampling devices.
Monoclonal antibodies (mAbs) have been extensively developed over the past few years, for the treatment of various inflammatory diseases. They are large molecules characterized by complex pharmacokinetic and pharmacodynamic properties. Therapeutic drug monitoring (TDM) is routinely implemented in the therapy with mAbs, to monitor patients' treatment response and to further guide dose adjustments. Serum has been the matrix of choice in the TDM of mAbs and its sampling requires the visit of the patients to laboratories that are not always easily accessible. Therefore, dried blood spots (DBS) and various microsampling techniques have been suggested as an alternative. DBS is a sampling technique in which capillary blood is deposited on a special filter paper. It is a relatively simple procedure, and the patients can perform the home-sampling. The convenience it offers has enabled its use in the quantification of small-molecule drugs, whilst in the recent years, studies aimed to develop microsampling methods that will facilitate the TDM of mAbs. Nevertheless, hematocrit still remains an obstacle that hinders a more widespread implementation of DBS in clinical practice. The introduction of novel analytical techniques and contemporary microsampling devices can be considered the steppingstone to the attempts made addressing this issue.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据